Last reviewed · How we verify
HEPLISAV
At a glance
| Generic name | HEPLISAV |
|---|---|
| Also known as | Hepatitis B Vaccine (Recombinant), Adjuvanted, Hepatitis B vaccine (recombinant), adjuvanted, HEPLISAV-B |
| Sponsor | Dynavax Technologies Corporation |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection site pain
- Fatigue
- Headache
- Unsolicited adverse events
Serious adverse events
- Serious adverse events (overall)
- Guillain-Barré syndrome
- Granulomatosis with polyangiitis
- Lichen planus
- Grave's disease
Key clinical trials
- Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Evaluation of Patients With Liver Disease
- Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
- Fungal Infection Susceptibility
- Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
- Evaluation of Patient Care Support for Cirrhosis and/or Liver Transplants
- The Mechanistic Biology of Primary Immunodeficiency Disorders
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |